Azitra (AZTR) Net Equity Issued and Repurchased (2025 - 2026)

Azitra (AZTR) posted Net Equity Issued and Repurchased of $215950.0 for Q1 2026, down 91.0% on a QoQ basis from $2.4 million in Q4 2025.

Azitra (AZTR) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends

Azitra's Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $215950.0 for Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $215950.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (changed N/A YoY) and the FY2025 annual result came in at $5.9 million, changed N/A from the prior year.
Net Equity Issued and Repurchased was $215950.0 for Q1 2026 at Azitra, down from $2.4 million in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $2.8 million in Q3 2025 and bottomed at $215950.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Nanobiotix	1,769.80 Bn	1,769.74 Bn	-	-
2	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-	-
3	BeOne Medicines	473.64 Bn	468.85 Bn	1.35 Bn	-
4	Vertex Pharmaceuticals	123.74 Bn	116.49 Bn	2.59 Bn	-
5	Regeneron Pharmaceuticals	71.73 Bn	62.97 Bn	3.31 Bn	163.10 Mn
6	Belite Bio	62.10 Bn	62.10 Bn	-	-
7	Argenx Se	54.68 Bn	49.49 Bn	1.41 Bn	-
8	Alnylam Pharmaceuticals	38.13 Bn	35.12 Bn	959.66 Mn	-
9	Revolution Medicines	36.21 Bn	36.21 Bn	-	141.90 Mn
10	Azitra	2.03 Mn	2.03 Mn	-	215,950.00

Download Data